Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
-
REGULATORY MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
-
BUSINESS MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
-
REGULATORY Average NHI-Market Price Gap of Listed Drugs at 7.6%: MHLW
December 3, 2021
-
REGULATORY Chuikyo Members Call for Restrictions in Re-Pricing Exclusions from Spillover Rule
December 2, 2021
-
BUSINESS Blaze at Hitachi Logistic Center Could Add to Drug Supply Woes
December 1, 2021
-
REGULATORY Japan Confirms 1st Case of Omicron Variant: MHLW
December 1, 2021
-
REGULATORY Alzheimer’s Drugs in Mind, MHLW to Float New Rule for Potential Super Big Sellers
November 30, 2021
-
BUSINESS Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
-
REGULATORY Japan Approves Jardiance for Heart Failure, Label Expansions for Opdivo and Keytruda
November 26, 2021
-
REGULATORY Pharma Pushes 2% Adjustment Rate Plus Certain Range in 2022 Drug Price Revision
November 26, 2021
-
REGULATORY Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
-
REGULATORY LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
-
BUSINESS Top 3 Japan Generic Makers Face Uphill Struggle Overseas in April-September: Jiho Tally
November 25, 2021
-
BUSINESS Japan Biz of Top 3 Generic Makers in H1 Impacted by GMP Issues, Substitution Demand: Jiho Tally
November 25, 2021
-
BUSINESS Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
-
ORGANIZATION 20% of Listed Drugs in Japan, Mostly Generics, Hit by Supply Issues: FPMAJ Survey
November 22, 2021
-
REGULATORY Japan OKs 56 Trillion Yen Stimulus Package, Spells Out Support for Japan-Made Drugs and Vaccines
November 22, 2021
-
BUSINESS Top 4 Wholesalers’ Average Operating Margin at 0.46% on Tough Price Negotiations: H1 FY2021 Earnings
November 22, 2021
-
REGULATORY Japan Panel Discusses Safety, Immunity Rules for Envisaged Emergency Approval Scheme
November 19, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…